glp-1 receptor agonist drugs in development research Market Size & Trends 2035 Strategies to Enhance the Therapeutic
Description
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
Foundayo and oral Wegovy have arrived
The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031
This class of drugs is commonly called glucagon-like peptide 1 (GLP-1) agonists.GLP-1 Agonists What is it?
Packaging and label may vary
